Relapsed/Refractory DLBCL: Therapeutic Options in the Third Line Setting

Videos

Focusing their discussion on therapeutic options for patients with R/R DLBCL, in the third line and beyond setting.

Navigating Toxicities in CAR T-Cell Therapy in R/R DLBCL

Clinical Oncologists focus their discussion on navigating toxicities specific to CAR T, highlighting cytokine release syndrome (CRS) and neurotoxicities.

Clinical Perspectives of CAR T in R/R Diffuse Large B-Cell Lymphoma

Experts share clinical perspectives on the use of CAR T for patients with DLBCL, in the R/R setting.

Data Updates: CAR T in the ZUMA-7 and TRANSFORM Trials for R/R DLBCL

Focused discussion on the latest updates of CAR Ts such as axi-cel and liso-cel from the ZUMA-7 and TRANSFORM trials, respectively.

The Role of CAR T-Cell Therapy in R/R DLBCL

Centering discussion on the role of CAR T-cell therapy for patients with R/R DLBCL.

Real-World Outcomes of Tafasitamab-Lenalidomide for Patients with R/R DLBCL

Panelists consider real-world outcomes for treating patients with tafasitamab-lenalidomide for R/R DLBCL.

Tafasitamab and Lenalidomide for R/R DLBCL

A comprehensive overview of tafasitamab plus lenalidomide for patients with relapsed/refractory DLBCL, highlighting data updates and the impact on clinical practice.

Treatment Selection in Second Line R/R DLBCL

Expert perspectives on treatment selection for patients with R/R DLBCL receiving second line therapy.

Evolving Practice Standards and Disease Progression Beyond Frontline Therapy for Patients with DLBCL

A brief discussion on evolving practice standards and clinical perspectives that help to inform selection of best therapy for patients with DLBCL that progress beyond initial therapy.

Overview of First-Line Treatment in Diffuse Large B-Cell Lymphoma

Key opinion leaders on diffuse large B-cell lymphoma management provide a review first-line treatment options. 

Haifaa Abdulhaq, MD, an associate clinical professor in Hematology and Oncology at the University of California, San Francisco (UCSF) and the director of hematology and the Hematology/Oncology Fellowship Program at UCSF Fresno, discusses the benefits of chemotherapy-free options in diffuse large B-cell lymphoma (DLBCL).

There is something to be said about the safety profile of tafasitamab and how it helps patients maintain quality of life, says Abdulhaq. Patients who have relapsed/refractory DLBCL and are transplant ineligible, are often older or have comorbidities. In this patient population, maintaining a balance between efficacy and a reasonable toxicity profile is essential, according to Abdulhaql; this is a benefit provided with tafasitamab. Lenalidomide (Revlimid) is another important chemotherapy-free, oral agent that provides value to these patients, concludes Abdulhaq.

Haifaa Abdulhaq, MD, discusses the benefits of chemotherapy-free options in diffuse large B-cell lymphoma.

Haifaa Abdulhaq, MD

Articles